ARAYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
ACCURAY INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$0.14−0.01 (-8.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
27.7%−12.5 pts over 5 years
Operating margin
-6.6%−12.2 pts over 5 years
Net margin
-12.2%−10.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -12.3% | -3.5% | +0.3% | +0.1% | |
| Gross profit | -24.2% | -10.2% | -6.9% | -3.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -55.7% | -9.5% | -80.1% | |
| Return on assets | -6.8% | -1.3% | -10.8% | |
| Current ratio | 1.09 | 1.83 | 1.50 | |
| Debt to equity | 3.54 | 2.58 | 3.55 | |
| Net debt to EBITDA | 9.65× | 2.07× | -5.80× | |
| Interest coverage | -0.6× | 1.3× | -0.8× | |
| Inventory turnover | 2.2× | 1.8× | 2.0× | |
| Capex to revenue | 1.3% | 0.6% | 1.5% | |
| Diluted shares | 82M | 92M | 123M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Accuray generated $39.68M from operations and spent $31.07M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$39.68M
Used
$31.07M
Capital expenditure$31.07M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-12.2%
×Asset turnover0.88×
×Equity multiplier7.44×
=Return on equity, FY2026-80.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -12.2% | 0.88× | 7.44× | -80.1% |
| FY2025 | -0.3% | 0.98× | 7.44× | -2.5% |
| FY2024 | -3.5% | 0.94× | 9.60× | -31.5% |
| FY2023 | -2.1% | 0.94× | 8.91× | -17.4% |
| FY2022 | -1.2% | 0.90× | 7.81× | -8.8% |
| FY2021 | -1.6% | 0.82× | 7.33× | -9.5% |
| FY2020 | 1.0% | 0.82× | 8.19× | 6.7% |
| FY2019 | -3.9% | 1.03× | 8.29× | -33.4% |
| FY2018 | -5.9% | 1.03× | 8.25× | -50.2% |
| FY2017 | -7.7% | 0.88× | 8.24× | -55.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$49.19M
- Cash generatingOperating cash flow above zero-$6.98M
- Return on assets improvedROA up on the prior year-0.3% → -10.5%
- Earnings backed by cashOperating cash flow above net income-$6.98M vs -$49.19M
- Less leverageLong-term debt to assets fell26.3% → 33.0%
- Better liquidityCurrent ratio rose1.65 → 1.50
- No dilutionShare count did not rise103M → 123M
- Gross margin improvedGross margin up on the prior year32.05% → 27.73%
- More efficientAsset turnover rose0.98 → 0.85